Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04171141
Previous Study | Return to List | Next Study

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04171141
Recruitment Status : Recruiting
First Posted : November 20, 2019
Last Update Posted : February 21, 2021
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE November 8, 2019
First Posted Date  ICMJE November 20, 2019
Last Update Posted Date February 21, 2021
Actual Study Start Date  ICMJE November 19, 2019
Estimated Primary Completion Date October 1, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 18, 2019)
  • Number of participants with Dose-limiting toxicities (DLT) in Cycle 1 [ Time Frame: Baseline up to 28 days ]
  • Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities [ Time Frame: Baseline up to approximately 24 months ]
  • Duration of Adverse Events (AEs) [ Time Frame: Baseline up to approximately 24 months ]
  • Number of Participants With Adverse Events (AEs) According to Severity [ Time Frame: Baseline up to approximately 24 months ]
  • Number of Participants With Adverse Events (AEs) According to Seriousness [ Time Frame: Baseline up to up to approximately 24 months ]
  • Number of Participants With Adverse Events (AEs) by Relationship [ Time Frame: Baseline up to approximately 24 months ]
  • Objective Response - Number of Participants With Objective Response for Dose Expansion (Part 2) [ Time Frame: Baseline (1st dosing) up to approximately 24 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 18, 2019)
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  • Incidence of Anti-Drug Antibody (ADA) an Neutralizing Antibodies (Nab) for PF-07062119 [ Time Frame: Up to approximately 24 months ]
  • Incidence of Anti-Drug Antibody (ADA) an Neutralizing Antibodies anti-PD1 [ Time Frame: Up to approximately 24 months ]
  • Incidence of Anti-Drug Antibody (ADA) an Neutralizing Antibodies (Nab) for anti-VEGF [ Time Frame: Up to approximately 24 months ]
  • Apparent Clearance (CL/F) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  • Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  • Terminal Half-Life (t1/2) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  • Objective Response - Number of Participants With Objective Response for Dose Escalation [ Time Frame: Baseline up to 24 months ]
  • Objective Response - Number of Participants With Objective Response for Dose Finding portion [ Time Frame: Baseline up to 24 months ]
  • Minimum Observed Plasma Trough Concentration (Cmin) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  • Progression-Free Survival (PFS) for Dose Expansion [ Time Frame: Baseline to measured progressive disease (up to 24 months) ]
  • Duration of Response (DR) for Dose Expansion [ Time Frame: Baseline up to approximately 24 months ]
  • Change from baseline of immune cells from tumor biopsies [ Time Frame: Baseline and Cycle 2, Day 1 (each cycle is 28 days) ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Official Title  ICMJE A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS
Brief Summary A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
Detailed Description This is a Phase 1, open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of PF-07062119 administered as a single agent in sequential dose levels and then in combination with anti-programmed cell death -1 protein (anti-PD-1) and in combination with an anti-vascular endothelial growth factor (anti-VEGF). In Part 1A, successive cohorts of patients will receive escalating doses of PF-007062119 and then in dose finding (Part 1B) with PF-07062119 in combination with anti-PD-1 and in combination with anti-VEGF. This study contains 2 parts, dose escalation with single agent (Part 1A) and then dose finding with PF-007062119 in combination with ant-PD-1 and in combination with anti-VEGF (Part 1B) followed by dose expansion arms as a single agent and PF-07062119 in combination with anti-PD 1 and in combination with anti-VEGF (Part 2).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Gastrointestinal Tumors
  • Colorectal Adenocarcinomas
  • Gastric Adenocarcinomas
  • Esophageal Adenocarcinomas
Intervention  ICMJE
  • Drug: PF-07062119
    PF-07062119
  • Drug: Anti-PD1
    Anti-PD1 PF-06801591
  • Drug: Anti-VEGF
    Anti-VEGF IV (bevacizumab)
Study Arms  ICMJE
  • Experimental: Dose Escalation
    Single Agent Dose Escalation
    Intervention: Drug: PF-07062119
  • Experimental: Dose Finding Anti-PD-1 Combination
    Part 1B PF-07062119 plus anti-PD-1
    Interventions:
    • Drug: PF-07062119
    • Drug: Anti-PD1
  • Experimental: Dose Finding anti-VEGF Combination
    Part 1B PF-07062119 plus anti-VEGF
    Interventions:
    • Drug: PF-07062119
    • Drug: Anti-VEGF
  • Experimental: Dose Expansion Arm A
    PF-07062119 as a Single Agent in CRC
    Intervention: Drug: PF-07062119
  • Experimental: Dose Expansion Arm B
    PF-07062119 in Combination with anti-PD-1 in CRC
    Intervention: Drug: PF-07062119
  • Experimental: Dose Expansion Arm C
    PF-07062119 in Combination with anti-VEGF in CRC
    Interventions:
    • Drug: PF-07062119
    • Drug: Anti-PD1
    • Drug: Anti-VEGF
  • Experimental: Dose Expansion Arm D
    PF-07062119 in Combination with either anti-PD-1 or anti-VEGF in various Tumor Types
    Interventions:
    • Drug: PF-07062119
    • Drug: Anti-PD1
    • Drug: Anti-VEGF
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 18, 2019)
110
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE October 1, 2023
Estimated Primary Completion Date October 1, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • For Part 1 and Part 2, diagnosis of advanced/metastatic colorectal, gastric or esophageal adenocarcinoma that is resistant to standard therapy or for which no local regulatory approved standard therapy is available that would confer significant benefit.
  • For Part 2, diagnosis of colorectal adenocarcinoma that is resistant to standard therapy or for which no standard therapy is available
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
  • Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)
  • Measurable disease as defined by RECIST 1.1 is required (Part 2)

Exclusion Criteria:

  • Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases
  • Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
  • Major surgery or radiation within 3 weeks prior to study entry
  • Last anti-cancer treatment within 4 weeks prior to study entry
  • Active or history of clinically significant autoimmune disease that required systemic immunosuppressive medication
  • Active or history of clinically significant gastrointestinal disease
  • Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry
  • Pregnant or breastfeeding female patients
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com
Listed Location Countries  ICMJE Japan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04171141
Other Study ID Numbers  ICMJE C3861001
GUCY2C ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP